Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

The Best Results Achieved So Far in Pancreatic Cancer

The Best Results Achieved So Far in Pancreatic Cancer

Pancreatic cancer surgery was followed by a comparison of adjuvant (preventive) standard chemotherapy with gemcitabine versus mFOLFIRINOX, the powerful treatment combination we routinely use for metastatic pancreatic cancer.

PRODIGE 24 / CCTG PA.6, a phase-3 randomized clinical trial, was presented by Dr. Thierry Conroy and colleagues from the Lorraine Cancer Center in Nancy, Institut de Cancerologie, France, at the 2018 ASCO annual meeting. The study reportedly enrolled 493 patients with nonmetastatic pancreatic ductal adenocarcinoma (classic pancreatic cancer) who had undergone surgery.

Because of its aggressive nature, pancreatic cancer carries a high risk of recurrence even after successful surgery. Recurrence occurs when microscopic residual cancer cells, invisible to the eye, left behind and spread throughout the body, become active. With the chemotherapy drug we have used as standard adjuvant treatment for more than a decade, gemcitabine , disease-free survival is around 1 year, whereas mFOLFIRINOX achieved nearly twice as long a disease-free survival (21.6 months). Comparing median overall survival with these two regimens yielded a striking difference: approximately 3 years (35 months) versus 4.5 years (54 months). These results can be called astonishing for a cancer such as pancreatic cancer, which is extremely difficult to treat.

pancreatic cancer asco 2018 adjuvant treatment mfolfirinox PRODIGE 24 CCTG study

When comparing the side effects of the two treatments, mFOLFIRINOX, a four-drug chemotherapy combination (a modified regimen containing oxaliplatin, leucovorin, irinotecan and fluorouracil), showed a marked increase particularly in hematological side effects such as reduced blood counts. However, the side effects were considered manageable.

Medical oncologist Dr. Conroy stated: "In our study, for the first time in adjuvant treatment of pancreatic cancer, mFOLFIRINOX chemotherapy demonstrated significant superiority over standard gemcitabine. Considering all the drugs used so far, the successful result we achieved with mFOLFIRINOX is good news for patients with pancreatic cancer." he said.

We believe that the full text and details of this study, which we expect to change our pancreatic cancer treatment practice, will be published shortly and rapidly incorporated into international treatment guidelines.

Sources

Thierry Conroy, Pascal Hammel, Mohamed Hebbar ve ark.
Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas.
2018 ASCO Annual Meeting - Abstract No: LBA4001

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

The Best Results Achieved So Far in Pancreatic Cancer

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy